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Qualitative Immunoassay for detection of 
Antibodies to HIV 1/2 in Oral Mucosal Transudate 
- A Diagnostic Study 
 
Introduction 
Acquired Immuno Deficiency syndrome is a fatal disease caused 
by a Retro virus called  Human Immuno Deficiency Virus which is a 
RNA virus and is characterized by profound Immunosuppression together 
with development of opportunistic infections, Secondary Neoplasm’s and 
neurologic manifestations5.  
Centers of Disease control modified AIDS definition6 in 1992 as 
“All people infected with HIV who have a CD4 lymphocyte count of      
< 200 cells per micro liters irrespective of clinical manifestations / who 
have one of the following 3 clinical conditions, Pulmonary tuberculosis , 
Recurrent pneumonia and Invasive cervical cancer”. 
WHO6 defined AIDS by the existence of atleast two of the major 
signs associated with atleast one minor sign in the absence of known case 
of immunosuppression such as cancer / severe malnutrition. Major Signs 
include Weight loss > 10% body weight, chronic diarrhoea > 1 month, 
prolonged fever > 1 month. Minor signs include persistent cough for > 1 
month, generalized pruritis dermatitis, recurrent herpes zoster, 
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Oropharyngeal candidiasis, chronic progressive / disseminated herpes 
simplex infections, and generalized lymphadenopathy. 
Epidemiology:  
 HIV infection /AIDS is a global pandemic. The current estimate of 
the number of cases of HIV infection among adults worldwide is 
approximately 37 million, two thirds of whom are in sub- Saharan Africa. 
50% cases are Women5. In addition 2.5 million children younger than 15 
are living with HIV/AIDS. According to Joint United nations Programme 
on HIV/AIDS1 in 2007, on a global scale, the HIV epidemic has 
stabilized, although with unacceptably high levels of new HIV infections 
and AIDS deaths. Globally, there were an estimated 33 million [30 
million–36 million] people living with HIV in 200711. The annual number 
of new HIV infections declined from 3.0 million [2.6 million- 3.5 
million] in 2001 to 2.7 million [2.2 million–3.2 million] in 2007.Overall, 
2.0 million [1.8 million–2.3 million] people died due to AIDS in 2007, 
compared with an estimated 1.7 million [1.5 million–2.3 million] in 
20016. India had an estimated 1.8 – 2.9 million HIV positive persons in 
2007, with an estimated adult HIV prevalence of 0.34% (0.25%–0.43%)2. 
The most rapid and well-documented spread of infection has occurred in 
State of Maharashtra (Bombay) and Tamilnadu. The HIV epidemic has 
occurred in waves in different regions of the world, each wave 
representing different characteristics depending on the demographics of 
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the country and region in question and the timing of the introduction of 
HIV into the population. 
Virology: 
Human Immuno Deficiency Virus type 1 and type 2, a RNA virus 
belongs to the Lentivirus a subfamily of Human Retrovirs6-9. HIV 1 and 
HIV 2 is the only Lenti Virus known to infect humans.  The hallmark of 
the HIV virus is the reverse transcription of its genomic RNA to DNA by 
the enzyme reverse transcriptase. Electron Microscopy shows that the 
HIV virion is an icosahedral structure containing numerous external 
spikes formed by the two major envelope proteins, the external gp 120 
and the transmemebrane gp 41. HIV type 1 and HIV type 2 are two 
subtypes of HIV which is associated with AIDS. Same Individuals can be 
infected with both HIV-1 and HIV-2. HIV-1 is more aggressive3 and 
more transmissible than HIV -2 .The transmission efficiency of HIV-1 
appears considerably greater than HIV-2 early in course of infection, 
which account for more rapid spread of HIV-1. There is a higher titre of 
autolog of neutralizing antibodies in HIV-2 infected individuals .These 
antibodies survive for a longer time. Various strains of HIV type 1 and 
HIV type 2 exists and have some significant nucleic acid and envelope 
differences.  These variants of HIV strains promote a rapid diseases 
progression.  
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                             HIV Virus Structure 
             
 
Pathogenesis:  
HIV primarily affects cell-mediated immunity binding to and 
infecting cells that have CD4 surface antigen. CD4 is found on T-helper 
cells, macrophages, monocytes, and colorectal cells possibly some brain 
cells. Disease progression is the result of HIV affinity for T4 cells which 
promote activity of cell mediated immune response primarily located in 
lymphoid tissue6-9. HIV binds to the CD4+Tcell via a specific high 
affinity interaction of the external envelope glycoprotein, gp120. HIV 
fuses with the cell using transmemebrane gp416. Major co-receptors 
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CCR5 and CXCR4 are required for fusion and entry into the cell. After 
fusion HIV genome is uncoated and internalized into the cell. Viral 
Reverse transcriptase mediates transcription of its RNA into double 
stranded DNA which is integrated into the genome of the infected cell 
through the action of the viral enzyme integrase, causing a latent 
infection.  From time to time, lytic infection is initiated releasing progeny 
virions which infect other cells. The long and variable incubation period 
of HIV infection is because of latency. As a result T4 cells decrease in 
numbers, T4: T8 cell ratio is reversed12. Infected T cells do not appear to 
release normal amounts of interleukin-2, gamma interferon, and other 
lymphokines. This has a marked damping effect on cell mediated immune 
response. Helper T cell activity is essential for optimal B cell function 
humoral mechanisms are also affected. Monocyte-macrophage function is 
also affected apparently due to lack of secretion of activating factors by 
the T4 lymphocytes. As a result of chemotaxis, antigen presentation and 
intracellular killing by monocytes / macrophages are diminished. The 
activity of NK cells and cytotoxic T lymphocytes is also affected9. 
Clinical manifestations of HIV infections are not primarily due to 
cytopathology but are secondary to the failure of immune responses and 
subsequently opportunistic infections6-9. 
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Mode of transmission / High Risk Factors:  
The Three Main Routes of Transmission are Sexual Contact, 
Intravenous drug abuse and perinatal exposure5-9. Infection may also 
occur from artificial insemination, organ transplantation and breast 
feeding. High Risk group include IV drug user using contaminated 
needles, homosexual and bisexual men and infants of HIV positive 
mothers3. Recently there has been a serious increase of HIV Positive 
women within heterosexual population. Unprotected receptive and anal 
intercourse is highest risk behaviour by far among homosexual. High risk 
sexual behaviour is increased in case of multiple partners and in case with 
sexually transmitted disease. There is no evidence HIV transmitted 
through contact with air environmental surface, casual contact even 
where people are living together. HIV may be found in variable numbers 
at various times during the course of disease in the lymph nodes , nervous 
system , blood , serum, semen, urine, breast milk  , saliva , tears and  
vaginal fluid . HIV does not survive for long outside5. 
Oral Manifestations of AIDS: 
 Characteristic Oral infection represents earliest manifestations of 
HIV infection. Some lesions may be of prognostic significant in 
development of AIDS. Some produces very serious discomfort and 
morbidity. Specific Oral lesions and concurrent different oral lesions are 
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indicators of severe immunosuppression. The predictive values of lesions 
indicating severe suppression ranked with the highest are Major Apthous 
Ulcer,  Necrotic Periodontitis, Kaposi’s Sarcoma, Long standing herpes 
simplex infection , Hairy leukoplakia and Xerostomia. Oral hairy 
Leukoplakia and Oral candidiasis are the most common and thus best 
prognostic indicators of the development of AIDS5. 
EC- Clearinghouse Classification of the Oral Manifestations of HIV 
diseases:66 (J Oral Pathol Med 1993; 22: 289-91, J Oral Pathol 
Med.2005; 34: 513-31) 
Group 1 lesions strongly associated with HIV infection: 
 Candidiasis 
  Erythematous 
  Pseudomemebranous 
 Oral Hairy Leukoplakia 
 Kaposi’s sarcoma 
 Non Hodgkin’s Lymphoma 
 Periodontal Diseases 
  Linear Gingival Erythema 
   Necrotizing gingivitis  
Necrotizing Periodontitis  
 
Group 2 lesions less commonly associated with HIV infection: 
  
Bacterial infections 
 Mycobacterium Avium-Intracellulare  
Mycobacterium tuberculosis  
Melanotic hyperpigmentation  
Necrotizing Stomatitis  
Salivary gland diseases   
Xerostomia  
Unilateral or bilateral swelling of major salivary glands 
Thrombocytopenic Purpura  
Ulceration not otherwise specified  
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Viral infections  
Herpes simplex Virus  
Human Papillomavirus lesions  
Condyloma Acuminatum  
Focal epithelial hyperplasia  
Verruca Vulgaris  
Varicella Zoster Virus  
Herpes Zoster Varicella 
 
 
Group 3 lesions seen in HIV infection: 
  
Bacterial infections  
Actinomyces Israeli  
Escherichia Coli  
Klebsiella Pneumonia  
 
Cat –Scratch diseases  
 
Drug –reactions  
Ulcerative  
Erythema Multiforme  
Lichenoid reaction 
Toxic epidermolysis  
Epitheliod bacillary angiomatosis  
 
Fungal infections other than Candida  
Cryptococcus neoformans  
Geotrichum candium  
Histoplasma capsulatum  
Mucormycosis  
Zygomycosis  
Aspergillus flavus  
 
Neurological disturbances  
Facial palsy  
Trigeminal Neuralgia  
Viral Infections  
Cytomegalovirus  
Molluscum Contagiosum 
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EC- Clearinghouse and WHO classification of Oral Manifestations of 
pediatric HIV disease66: 
Group 1 lesions commonly associated with pediatric HIV infection 
Candidiasis 
 Erythematous candidiasis  
Pseudo membranous candidiasis  
Angular Chelitis  
Herpes simplex virus infection  
Linear gingival erythema  
Parotid enlargement  
Recurrent apthous ulcers  
Minor  
Major  
Herpetiform 
 
Group 2 lesions less commonly associated with pediatric HIV 
infection 
 
Seborrheic dermatitis  
Bacterial infection of oral tissues  
Necrotizing ulcerative stomatitis  
Periodontal diseases  
Necrotizing (ulcerative) gingivitis   
Necrotizing (ulcerative) periodontitis  
Viral infections  
Cytomegalovirus  
Human papilloma virus  
Varicella –Zoster virus  
Herpes Zoster  
Varicella 
 Xerostomia 
 
Group 3 lesions strongly associated with HIV infection but rare in 
children 
 
Neoplasm  
Kaposi’s sarcoma  
Non-Hodgkin’s lymphoma  
Oral hairy leukoplakia  
Tuberculosis –related ulcers 
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Laboratory Tests:  
 Laboratory diagnosis for diagnosis of HIV includes specific tests 
for HIV as well as tests for immunodeficiency7-9. 
A. Immunological tests 
B. Specific Test for HIV infection 
A. The Immunodeficiency of the individual can be established by the 
following parameters. 
a. Total Leukocyte / Lymphocyte count 
b. T cell subset assay: Absolute CD4 & Tcell Count, T4: T8 
ratio. 
c. Platelet Count  
d. Raised IgG / IgA level 
e. Lymph node biopsy 
B. Specific  Tests for HIV infection:  
The specific test for detecting HIV infection depends on 
demonstration of HIV antigens and its components, antibodies, isolation 
of Virus. 
Antigen detection: 
 The Viral antigens may be detectable in blood after about 
two weeks of HIV infection. The major Core antigen P24 is the earliest 
viral marker to appear in blood. Free P24 disappears from circulation and 
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remain absent during long asymptomatic phase, but antibody bound P24 
antigen can be demonstrated. P24 capture assay which use anti P24 
antibody is positive in 30% of HIV individuals the test is used to 
diagnose patients recently exposed to HIV infection where antibody test 
is negative7-9. 
 Viral Isolation: 
  Viral Isolation is not suitable as a routine diagnostic test. 
The Risk involved Virus isolation is to be considered and has to be 
carried out only in laboratories with adequate facilities. The Technique of 
Viral isolation is by Co-cultivation of the patients lymphocytes with 
uninfected lymphocytes in the presence of interleukin -2. Viral replication 
can be demonstrated by Reverse transcriptase activity as well as by the 
antigens9. 
Polymerase Chain Reaction: 
  Polymerase chain reaction has become the gold standard for 
diagnosis of all stages of HIV infection. The PCR tests are complex and 
costly and are indicated only when other methods cannot give a definitive 
result9. 
Antibody Detection: 
The antibody test which is current in practice is ELISA, Rapid serum 
tests, Rapid Salivary and Urine assays and Western Blot6.  
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ELISA: 
ELISA is a highly specific screening test to test HIV 
antibody. Direct solid phase antiglobulin ELISA is the method most 
commonly used. The antigen is obtained from HIV grown in continuous 
T lymphocytes cell line or by recombinant techniques and should 
represent all groups and subtypes of HIV-1 and HIv-2. The antigen is 
coated on micro titre wells or other suitable solid surface. The test serum 
is added and if the antibody is present, it binds to the antigen. After 
washing away the unbound serum, antihuman immunoglobulin linked to 
a suitable enzyme is added, followed by a color –forming substrate. If test 
contains anti – HIV antibody, a photo metrically detectable color is 
formed which can be read by special ELISA readers. ELISA is simple 
and relatively inexpensive but false positive reactions are not uncommon, 
while ELISA is ideal for screening several serum samples at a time, it is 
inconvenient for testing single samples quickly. A number of ‘ rapid 
tests’ have been introduced for this purpose such as cylinder or cassette 
ELISA, immunochromatographic, coated particle agglutination, 
immunoperoxidase or dip stick tests. Tests using finger-Prick blood, 
saliva and urine have also been developed7-9.  
If ELISA is positive, a confirmatory Western blot test is performed 
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Western Blot: 
  Western Blot is considered ‘Gold Standard’ confirmatory 
tests. Identifies antibodies to HIV proteins and glycoprotein and a 
positive test provides evidence of previous HIV exposure. In this test HIV 
proteins separated according to electrophoretic mobility by 
polyacrylamide gel electrophoresis are blotted onto strips of 
nitrocellulose paper. These tests are reacted with test sera and then with 
enzyme conjugated antihuman globulin. A suitable substrate is added 
which produces color band where the specific antibody has reacted with 
the separate viral protein. The position of the band on the strip indicates 
the antigen with which the antibodies have reacted with the separate viral 
proteins. In a positive serum bands will be seen with multiple proteins, 
typically with P24 (gag gene), P31 (pol gene) and gp41, gp120, gp160 
(env gene). A positive reaction with proteins representing three genes 
gag, pol, and env is conclusive of HIV infection. Western blot is a very 
useful confirmatory test but the interpretation remains subjective and 
demands considerable experience. If no definitive result can be given 
then, it may be necessary to have p24 assay done.  
 However since the test is costly, the practice now is to perform 
either two different types of ELISA or an ELISA with any of the rapid 
tests. A serum positive in both tests is considered positive. When in doubt 
retesting after 1 or 2 months may be useful. However serological 
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diagnosis of infections may not always be reliable in aids as antibody 
formation may be affected by the immune deficiency. 
 
Oral Tests for HIV antibody9:  
 Various Oral Tests to detect HIV antibody either in Whole saliva 
or Oral Mucosal Transudate have become popular in recent years though 
it have been introduced long before. The possibility that saliva and oral 
fluids could be used for HIV screening and Diagnosis of HIV infections 
have been known since 1986. Oral Screening tests for HIV uses either 
IgA antibody of saliva or IgG antibody of Oral fluids. The advantages 
over serum screening test are ease of collection, safety, compliance and 
cost. Antibodies to Human Immuno deficiency virus type 1 have been 
found in various body fluids such as saliva, breast milk, cervical 
secretions and semen. The advantage of rapid HIV tests particularly with 
oral fluid specimens, include increased availability of testing among 
populations at high risk for HIV infection and increased receipt of test 
results among those tested 
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   Laboratory Diagnosis of HIV Infection- Flow Chart9 
 
 
 
 
Diagnosis of associated Diseases 
• Immunological aberrations 
• Opportunistic infections 
• Carcinomas and sarcomas. 
Detection of causative virus 
Laboratory Diagnosis of HIV infection 
ELISA 
• Direct 
• Indirect 
• Competitive  
Confirmatory tests 
• Radioimmunoassay 
• Indirect immunofluorescent test  
• Western Blot 
Virus 
Isolation 
Antibody 
detection 
Molecular level detection 
• Dot Blot Hybridization 
• PCR 
• Gene sequencing 
• Synthetic polypeptide 
Antigen Detection 
• ELISA 
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    Aims and Objectives 
Aims: 
This Study was designed to evaluate “HIV 1/ 2 OMT Test”, a new 
simple Oral Mucosal Screening test for Human Immunodeficiency Virus 
Type 1(HIV -1) and Human Immunodeficiency Virus Type 2 (HIV -2) & 
to compare its Sensitivity and Specificity with Serum Screening assays 
like ELISA and Rapid Serum assay. 
Objectives: 
 The main Objective of this Study is Qualitative analysis of 
antibodies to HIV-1 and HIV-2 in Oral Mucosal Transudate of Known 
HIV Positive Individuals & clinically suspected cases of HIV infection. 
Also Oral Screening antibody tests are compared with Serum Screening 
antibody tests to assess the accuracy, reliability, specificity and sensitivity 
of oral tests. 
 
• Qualitative detection of HIV antibodies in Oral mucosal transudate 
of Known HIV individuals. 
• Qualitative Detection of HIV antibodies in Oral Mucosal 
transudate of clinically suspected cases of HIV infection and 
comparison with serum screening assays. 
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Review of Literature 
Virology, Immunopathogenesis & Transmission of HIV: 
Nicholas G. Mosca, Alicia Rose Hathorn (2006)65  discussed the 
mucosal resistance to HIV. The studies of Protective anti HIV-1 immune 
response in mucosal tissues such as oral cavity are in progress. The first 
line of defense against mucosal HIV infections begins with virus 
neutralizing immunoglobulin or antibodies. In the oral cavity, secretory 
IgA produced by sub epithelial plasma cells is trancytosed by epithelial 
cells. IgG is transferred from blood by passive diffusion through gingival 
sulcus.  
 
Jennifer L.Cleveland (2003)71 evaluates the risk of occupational 
exposure of HIV to dental health care professionals (DHCP). Information 
available from the centers of Disease Control and Prevention (CDC) 
indicates that the risk of transmitting HIV to DHCP remains very small. 
Prospective studies worldwide indicate that the average risk of HIV 
infection after a single percutaneous exposure to HIV infected blood is  
0.3%; after an exposure of mucous membrane in the eye , nose , or mouth 
approximately 0.1%. The precise risk of transmission after skin exposures 
is not known but is believed to be even smaller. Several factors affect the 
risk of HIV transmission after an occupational exposure. Laboratory 
studies have found that if needles that pass through latex gloves are solid 
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rather than hollow –bore or are of small gauge, they transfer less blood. 
In a retrospective case control study of health care professionals, an 
increased risk for HIV infection was associated with exposures to a 
relatively large volume of blood. The risk also was increased if the 
exposure was to blood from patients with terminal illness, possibly 
reflecting the higher titre of HIV in late- stage AIDS. Standard methods 
to prevent occupational exposure in dental settings include hand washing, 
use of barrier precautions and careful handling and disposal of sharp 
instruments.  
 
Lauren L.Ptton (2003)70 state that primary route of transmission of HIV 
are sexual, blood-borne and vertical. The oral cavity represents a unique 
site for potential mucosal transmission. Epidemiological evidence 
however suggests that oral transmission is rare despite detectable virus in 
saliva and oral mucosal cells of infected persons. Several endogenous 
mucosal antiviral factors such as virus- specific antibodies and soluble 
proteins are thought to play a critical role in preventing oral HIV 
transmission. 
 
Eliaz Kaufman, Ira B. Lamster (2002)10 Reviewed the diagnostic 
applications of Saliva for systemic diseases. As a diagnostic fluid, saliva 
offers distinctive advantage over serum because it can be collected non 
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invasively. Saliva also provides cost effective approach for the screening 
of large populations. Analysis of saliva may be useful in the diagnosis of 
hereditary disorders, autoimmune diseases, malignant and infectious 
diseases and endocrine disorders as well as in the assessment of 
therapeutic levels of drugs and monitoring of illicit drug use. They state 
that studies have demonstrated that the diagnosis of infection with the 
human immunodeficiency virus based on specific antibody in saliva is 
equivalent to serum in accuracy and therefore applicable for both clinical 
use and epidemiological surveillance. Antibody to HIV in whole saliva of 
infected individuals which was detected by ELISA and western blot assay 
correlated with serum antibody levels. As compared with serum 
sensitivity and specificity of antibody to HIV in saliva for detection of 
antibody to HIV in saliva are between 95% and 100%. Salivary IgA 
levels to HIV decline as infected patients become symptomatic. It was 
suggested that detection of IgA antibody to HIV in saliva may therefore 
be a prognostic indicator for the progression of HIV infection. Analysis 
of antibody in saliva is a simple diagnostic test for HIV compared with 
serum. Saliva can be collected non-invasively which eliminates the risk 
of infection for the health care workers. Furthermore viral transmission 
via saliva is unlikely since infectious virus is rarely isolated from the 
saliva. Several salivary and oral fluid tests have been developed for HIV 
diagnosis. Orasure is a testing system that is commercially available used 
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for diagnosis of HIV infection. The test relies on the collection of Oral 
mucosal transudate and IgG antibody. IgG antibody to the virus is the 
predominant type of anti- HIV immunoglobulin. Different pathologic 
lesions which are relatively common in HIV – infected individuals do not 
appear to influence the results. In conclusion, collection and analysis of 
saliva/ oral fluid offer a simple, safe well tolerable and accurate method 
for diagnosis of HIV infection. 
 
Herenia.P.Lawrence (2002)11 explores the recent research on salivary 
biomarkers of systemic illness, potential clinical and research 
applications of diagnostics based on oral fluids. Salivary biomarkers are 
used in monitoring general health and in the early diagnosis of disease. 
Disorders and diseases in which saliva may aid in diagnosis include 
human immunodeficiency virus seropositivity, cancer and preterm labor. 
Test using saliva as a diagnostic tool have made substantial inroads into 
an array of clinical and research areas such as virology, immunology, 
microbiology , endocrinology, epidemiology and forensics. The 
introduction of Polymerase chain reaction has lead to the use of oral 
fluids as a source of microbial DNA for detecting viruses and bacteria. In 
addition onset and severity of infectious diseases can be determined by 
the presence of antibodies to micro organism present in saliva and oral 
cavity. Researches have demonstrated that saliva tests for antibodies to 
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HIV represent a non-invasive alternative to quantification of antibodies in 
blood.  
Laboratory diagnosis of HIV infection: 
Stekler JD etal (2009)14 state that antibody tests have longer window 
periods after HIV acquisition than do nucleic acid amplification tests 
(NAATs). They studied HIV antibody testing to homosexual men using 
OraQuick Advance Rapid HIV 1/2 antibody tests on oral fluid and finger 
stick blood specimens and compared with Enzyme Immunoassay. They 
concluded that rapid antibody tests are less sensitive than enzyme 
immunoassay during early HIV infection. NAAT should be integrated 
into HIV testing programs that serve populations that undergo frequent 
testing and that have high rates of HIV acquisition, particularly if rapid 
HIV antibody testing is employed. Antigen –antibody combination assays 
may be reasonably sensitive alternative to HIV NAAT. 
 
Louie B (2009)15 assessed the sensitivity and specificity of first, second, 
third generation EIA for detection of antibodies to HIV -1 in oral fluid. 
The performances of three blood-based immunoassays test kits were 
compared with regard their ability to detect HIV-1 antibody in oral fluid. 
It was found that these three kits differ in their ability to detect HIV-1 
antibody. Notably, a third generation EIA which has been shown to 
possess superior sensitivity for antibody detection in plasma appears to 
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possess no sensitivity advantage for detecting HIV-1 antibody in oral 
fluid. 
Anthony T.Vernillo etal (2007)35 stated that latest Centres of Disease 
Control and Prevention (CDC) guidelines recommend routine HIV 
screening for a large segment of the population, given that the individual 
understands that HIV test will be performed unless he or she declines 
testing. Knowledge of HIV infection can increase early access to care and 
treatment and reduce further transmission. A rapid non-invasive test for 
HIV infection from oral fluid have recently gained importance and offers 
two distinct advantages 1) Results are available within 20 minutes, 
thereby eliminating a long waiting period 2) It has sensitivity and 
specificity comparable to blood testing. A preliminary positive test result 
must be confirmed with a Western Blot or by a standardized laboratory 
procedure. Important Ethical and legal issues must be resolved before the 
successful implementation of HIV testing in dental setting. The 
integration of HIV testing into dental practice is important and a policy of 
screening patient in dental office will contribute to a major advance in 
public health. Aside from legal and ethical considerations of HIV testing 
strategies and the education and training that would enable dentist to use 
salivary diagnostics for HIV infection, the implementation of and barriers 
to HIV testing in dental practice are of primary importance. HIV testing 
in dental settings will require that clinicians understand the legal and 
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moral requirements of privacy and confidentiality. A positive test result 
may lead to social ostracism, stigmatization in health care settings and 
employer discrimination. If a dentist administers the HIV test on oral 
transudate then he or she must give the preliminary results to the patient 
and then refer the patient to physician for follow-up confirmatory testing. 
Depending upon state law many clinics would be required to offer pre test 
and post test counseling.  Rapid HIV testing in dental practice is now 
gaining momentum , suggesting that dentist must be willing to include 
such testing within their standard of health care delivery. Establishing 
new practices with rapid  HIV testing in the dental setting will likely 
result initially from dentists currently in practice who wish to receive 
training in the use of the rapid test and counseling patients as part of their 
standard of care, positioning dentists at the leading edge of this important 
paradigm shift.  
 
Roberts KJ etal (2007) reviewed the Outcomes of blood and oral fluid 
rapid HIV testing from 2000-2006 regarding four outcomes of rapid HIV 
testing:  rates of client acceptance; rates of clients receiving their results; 
rates of entry into the medical care for those found to be HIV positive and 
the efficacy of prevention counselling after testing. A total f 116 studies 
in peer –reviewed journals were screened. Twenty six met the screening 
criteria and were selected for review. They stated considerable variation 
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was found in client acceptance rates with the highest rates among 
pregnant women in labor and delivery units and lowest rates in needle 
exchange and bath- house settings.  Three studies on entry into medical 
care among those who were newly identified as positive were 47%, 82%, 
and 97% of clients adhering to first medical appointments. No long term 
medical follow up studies were available. Only one study evaluated the 
efficacy of prevention counseling after rapid testing and found no 
statistically significant differences in number of sexually transmitted 
diseases conventional versus rapid HIV testers contracted. 
Delaney KP (2006)32 evaluated the performance of a rapid HIV antibody 
test used with whole blood and oral fluid. In diverse settings in four 
studies, the OraQuick test showed high sensitivity and specificity for HIV 
antibody in whole blood and oral fluid specimens. Slightly more false-
positive and false-negative results occurred with oral fluid than with 
whole blood, but performance with both specimen types was similar to, 
or better than, that of conventional EIAs 
 
Gottfried TD (2006)27 stated that the testing and counseling of persons at 
risk for infection with HIV and their subsequent treatment remains the 
primary tool to curb worldwide transmission of the virus. Rapid HIV tests 
address the need in the developing world for accurate, easy-to-use tests 
that do not require laboratory equipment or highly trained professionals 
 25
for implementation or refrigeration for storage. Calypte Biomedical has 
recently developed the Calypte AWARE HIV-1/2 OMT antibody test 
using oral fluid samples. This test has demonstrated high sensitivity and 
specificity for specimens collected in target areas where increased testing 
is needed. The inexpensive dipstick format in combination with the use of 
an alternative fluid to blood provides an improved testing procedure for 
areas with limited resources. 
 
Wesolowski LG (2006)23 did a post- marketing surveillance of Oral 
Quick whole blood and oral fluid rapid HIV testing. They state that 
Whole blood Ora Quick specificity was 99.98%, positive predictive value 
99.24%, the median oral fluid specificity was 99.89% and positive 
predictive value was 90%. 
 
Constantine NT, Kabat W (2005)38 updated the laboratory diagnosis 
and monitoring of HIV infection. They stated that the simple and more 
accurate diagnostic tools have become available, particularly for early 
detection and to monitor treatment in those who receive anti-retroviral 
treatment. Laboratory tests range from simple antibody tests to more 
sophistical methods that are used to monitor disease progression and 
identify drug resistance. These tools can assist physicians, medical 
practitioners and laboratory personnel to select suitable diagnostic tools 
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for the diagnosis, screening, monitoring of disease progression and for 
detection of drug resistance to anti-retroviral therapies. 
 
Lauren L.Ptton (2003)70 state that standard serologic HIV antibody test 
methods consists of screening enzyme liked immunosorbent assay 
(ELISA) and confirmatory western blot tests. Technologic advances have 
resulted in the ability to easily and safely collect and test oral fluids for 
antibodies to HIV-1.  In 2002, a rapid enzyme immunoassay HIV 
antibody antibody screening test that yields results in 20 minutes was 
approved by US FDA for use with blood. Clinical trials continue to 
improve this rapid test designed for use with oral mucosal transudate. 
Rapid test at the point of care facilities occupational-exposure post 
exposure prophylaxis decisions and may have value in identification of 
newly infected individuals. HIV testing requires written consent in most 
states and under most circumstances should be accompanied by pre-test 
and post-test prevention counseling according to CDC guidelines.  
 
King SD etal (2000)43 compared testing saliva and serum for detection of 
antibody to Human Immunodeficiency virus in Jamaica, West Indies. 
This study evaluated the OraScreen HIV Rapid Test, new simple saliva 
screening EIA for anti HIV1&2 and to compared the sensitivity and 
specificity with the standard serum anti HIV screening EIA in current use 
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in Jamaica. OraScreen HIV Rapid test showed 100% specificity and 
100% sensitivity in 257 volunteers of a family planning clinic and 52 
volunteers from a HIV infected individuals. 
 
Sy FS Rhodes SD etal(1998)45 studied the acceptability of Oral fluid 
testing for HIV antibodies in gay bars in a rural state and stated that oral 
fluid testing is acceptable and effective in reaching individuals who do 
not usually access traditional testing sites. 
 
Sangare KA, Koffi AR (1997)48 evaluated the potential of saliva for 
detection of antibodies and seroconversion in HIV individuals. They 
tested serum of 1023 patients with Abbott recombinant HIV1/HIV 2 
EIA and the same samples with Wellcozyme GACELISA for saliva. 
They showed salivary ELSA test was 98.69% sensitive and 100% 
Specific. This Study shows that testing saliva is effective for determining 
HIV status early in seroconversion. 
 
PJ. Lamey etal (1996)49 collected various components of saliva, namely 
mixed saliva, crevicuar fluid and minor gland secretions were collected 
from 63 known HIV antibody seropositive patients. A commercial test 
system Wellcozyme HIV 1/2 and an antibody capture ELISA were 
compared for sensitivity against all components. Sensitivity of HIV 1/ 2 
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was 100% in 123 mixed saliva, 121 parotid saliva and 127 labial fluid 
samples and 98% in 99 submandibular samples and 127 crevicular fluid 
samples.  Mixed saliva was most easily conveniently and effectively 
collected using a plain Salivette. According to this study the most 
effective sensitive method for demonstrating anti-HIV antibody is to 
collect mixed saliva with the plain Salivatte system and assay anti-HIV 
antibody levels by GACELISA. 
 
Mortimer PP , Parry JV(1994)52 state that salivary tests for anti-HIV 
offer advantages  of convenience , economy and safety and are more 
acceptable to subjects than blood tests. Further evaluation of the 
collection devices and assays, the introduction of safeguards against 
inadequate sampling and the development of suitable confirmatory assays 
are required. When these deficiencies have been met, salivary tests may 
supercede tests on serum for HIV and also other infection. 
 
Mortimer PP etal (1994)52 stated that salivary tests for anti HIV offer 
advantage of convenience, economy and safety and are more acceptable 
to subjects than blood tests. Further evaluation of collection devices and 
assay, the introduction of safe guard against inadequate sampling and the 
development of suitable confirmatory assays are required. When these 
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deficiencies have met salivary test may supercede tests on serum for HIV 
and also other infections. 
Shriniwas, Srivastava L (1994)51 analyzed the various laboratory 
diagnosis of HIV infection states that Detection of HIV –specific 
antibodies can be done by using one or more screening procedures, 
ELISA, rapid tests and simple tests. Supplemental tests like Western blot, 
immunofluorescence assay (IFA), virus isolation may confirm a positive 
findings and provide additional information. 
 
Matsuda S etal (1993)54 studied the characteristics of IgA antibodies 
against HIV-1 in sera and saliva from HIV- seropositive individuals in 
different clinical stages  and the results indicate that IgA antibodies are 
regulated independently from IgG antibodies and that the mucosal 
immune system is impaired in the early in the symptomatic phase of HIV 
infection. Detection of IgA antibodies may be useful in the prognosis of 
the diseases in HIV – infected individuals. 
Klaus Stark etal (1993)53 state that salivary antibody testing in 
saliva/oral fluid is an efficient tool for large scale epidemiological studies 
when standard salivettes are used for sample collection. 
Archibald etal (1990)61 in their study concluded that the presence of 
antibodies in saliva indicates that it is possible to stimulate production of 
secretory antibodies using vaccines against rgp 120. The development of 
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secretory antibodies may be necessary for protection against HIV 
infection. The presence of antibodies in saliva may inhibit the 
transmission of the virus across the mucosal membranes. 
Oral manifestations: 
Cristina Frezzini etal (2005)66 reviews current trend of HIV disease of 
the mouth and stated that number of oral lesions presently not included in 
the EC Clearing house classification of Oral manifestations include : 
Exfoliative chelitis, eruptive chelitis associated with HAART, sub 
mucous fibrosis , brown hairy leukoplakia , petechiae oral erythema , 
ranula and chelitis glandularis. The HAART related oral lesions seem to 
be most commonly reported in individuals in the developed world. Oral 
candidiasis has been associated with a more frequent progression to AIDS 
and has been used as a clinical marker to define the severity of HIV 
infection. Pseudo membranous candidiasis is the most common clinical 
presentation. Resistance by HSV to acyclovir therapy can arise in HIV 
diseases although cidofovir proved to be clinically effective. Non 
Hodgkin’s lymphoma is recognized as an AIDS defining condition in 
HIV infected individuals and is included in the oral lesions associated 
with HIV infection. Human papilloma virus has been increased in the 
mouth of HIV infected individuals in patients under HAART and is of 
aetiological significance in the development of oral squamous cell 
carcinoma. Highly active retroviral therapies generally reduce the 
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frequency and severity of most oral lesions associated with HIV diseases. 
The molecular epidemiological of the common oral infection is well 
characterized; however increased use of high dose of antimicrobials has 
lead to the development of drug resistance oral microbes. 
 
Lauren L.Ptton (2003)68 state that dentist may play a role in diagnosing 
HIV when medical history taking and oral examination reveal risk and 
clinical signs of possible immune suppression. Oral lesions, specifically 
intraoral Kaposi’s sarcoma, oral candidiasis and oral hairy leukoplakia 
may be first clinical manifestations of HIV and have been shown to have 
relatively high positive predictive value for HIV infection.   
 
Lauren L Patton etal (2000)70 studied the changing prevalence of oral 
manifestations of Human Immunodeficiency virus in the era of protease 
inhibitor therapy. They have reduced the viral replication which often 
results in increase in CD4 Counts of more than 100 cells/mm3. Parotid 
gland enlargement and Xerostomia associated with HIV –salivary gland 
disease appears to be on the rise. The observed increase in HIV salivary 
gland disease results from a similar lymphoproliferartive reactivation 
stimulated by HAART. Destructive immune mediated periodontal 
diseases, Oral Candidiasis and Kaposi’s Syndrome appear to be on the 
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decline whereas HIV –Salivary gland diseases and oral warts are 
increasing significantly. 
 
Anderdorf etal (1998)72 studied the oral manifestations of HIV infection 
in 600 South African patients and concluded that one or more lesions are 
seen in 60.4% 0f cases. Combined candidal infections were evident in 
37.8%, hairy leukoplakia 19.7% and combined gingival and periodontal 
lesion in 8.5%.  Lesions less commonly recorded include oral ulcerations 
and Kaposi’s sarcoma. The clinical range of lesions seen in similar to 
those reported elsewhere, but socio-cultural differences allowed no 
reliable comparison. 
 
Greenspan.D, Greenspan JS (1993)76 state that oral lesions represent 
some of the earliest signs of HIV infection and may be the prognostic 
significance in the subsequent development of AIDS and may if not 
treated produces significant morbidity. Oral examination is an important 
part of any physical examination and nowhere is this more important than 
in the case of suspected HIV infection. Oral candidiasis is a diagnostic 
monitor of AIDS in an HIV infected individual.  
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Materials and Methods 
This Study was conducted in Department of Oral Medicine and 
Radiology, Tamilnadu Government Dental College and Hospital, 
Chennai -3; Institutional Ethical committee’s approval had been got. 
Informed consent of each patient was obtained before conducting the 
study. 
Duration of Study: Oct 2008-Oct 2009 (1yr) 
Inclusion Criteria: 
Sample Size: 
Total Number of Patients: 50  Out of Which  
25- Clinically Suspected Cases of HIV infection. 
25- Known HIV Sero-Positive Individuals. 
Age Group: 
 All patients of age 20- 60yrs of age male/ female were included in 
the study. Informed Consent of all the patients was obtained. All Subjects 
should be thoroughly examined which include medical history, contact 
history, a physical examination and clinical oral examination. HIV 
patients who were severely ill and those who were not willing to 
participate in the study were excluded from the study. 
Study Design: 25 patients were selected under the category of suspected 
cases of HIV infection. High risk group patients, patients with any sign / 
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symptom suggestive of HIV infection are included in the list of suspected 
cases of HIV infection. High Risk group individuals include homosexual 
men, Intravenous drug users, Sex workers, Children born to HIV infected 
patients. Patients with General symptoms like Sudden weight loss, 
chronic fatigue and tiredness, Recurrent Fever and cough, atypical severe 
dermatological lesions, H/0 Tuberculosis and Oral symptoms such as 
Oral Candidiasis, Atypical Herpetic Lesions, Non healing Ulcers, 
Idiopathic severe burning sensation of Oral Mucosa, Severe Aggressive  
Gingivitis and periodontitis refractory to treatment are considered as 
clinically suspected cases of HIV infection. Selected cases are subjected 
to OMT Test and compared with Rapid Serum tests of antibody detection. 
Rapid Serum antibody detection test include 3 consecutive serum tests 
namely Type I COMBAIDS HIV 1+2 Immunodot assay, Type II SD 
BIOLINE HIV 1/ 2 Rapid serum assay, Type III Pareeshak HIV 1/2  
Triline serum assay . The individuals who are tested positive to Type I 
Rapid serum assays are tested with other two tests and the results are read 
as positive to HIV infection only when the patient is positive to all the 
three Rapid serum assays. Pre and Posttest counseling was mandatory 
before the patients are subjected to HIV tests.  
25 cases Of Known HIV patients are used as control group and are tested 
for Oral Mucosal Transudate test  
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Armamentarium: 
• Diagnostic Instruments (Fig 1) 
• Universal barriers: Disposable gloves, Masks, Protective 
goggles(Fig 3) 
• Timer 
• Test KIT : Aware HIV 1/2 OMT Kit consisting of (Fig 2) 
o Foil pouch containing Oral fluid test strip and desiccant. 
o Capped test tube containing oral fluid sample buffer 
o Oral fluid sample collection swab 
• Biomedical Waste Disposal system ( Fig 11-13) 
Aware Oral Mucosal Transudate Test:  
 A qualitative, visually read, in vitro immunoassay for the detection 
of antibodies to Human Immunodeficiency Virus Type 1(HIV- 1) and 
Type 2 (HIV-2) in human oral mucosal transudate specimens. Aware 
HIV 1/2 OMT test is introduced by Calytype Biomedical corporation, 
USA. It is intended for use as appoint of care aid in the clinical diagnosis 
of HIV infection. The test may be used as a component of a multi- test 
rapid algorithm in conjunction with other approved HIV antibody assays. 
Individuals infected with HIV produce antibodies against the HIV viral 
proteins. Testing for the presence of these antibodies in bodily fluids 
(blood, urine, and oral fluid) is an accurate aid in diagnosis of infection. 
The Aware HIV 1/2 OMT test is composed of a single – use test device, 
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an oral fluid specimen, collection swab and a tube of oral fluid sample 
buffer. The test utilizes a proprietary lateral flow immunoassay 
procedure. The assay test strip is compromised of several materials that 
provide the matrix for the immunochromatography of the specimen. The 
assay strip contains recombinant regions of HIV -1 gp41 and HIV -2 gp 
36 transmembrane proteins  and a goat anti human IgG F ( ab’) 2 
fragment antibody in- capture procedural control immobilized onto the 
nitrocellulose in the test zone and the control zone, respectively. The oral 
fluid swab is placed vertically into the test-tube of fluid buffer. The liquid 
in the swab is expressed out and the used swab is discarded. The assay 
strip is then placed vertically into the test tube containing the specimen / 
buffer mixture. As the diluted specimen migrates up the assay test strip, it 
rehydrates a reddish Protein A- colloidal gold reagent on the strip and 
IgG specimen becomes bound to the protein A / colloidal gold particles to 
form IgG / conjugate complex. The complex then migrates up the strip 
and first encounters the test zone of the assay strip containing the HIV 
antigens. If the specimen contains antibodies to HIV, IgG/conjugate 
complex binds to the antigen and becomes immolized at the antigen line 
in the test zone and a reddish colored line appears. In a validity performed 
test, this indicates a reactive result. The intensity of the line is not 
proportional to the amount of antibody present in the specimen. The 
Specimen/conjugate mixture continues to migrate up the assay strip until 
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it encounters the Control Zone. The Control Zone contains anti human 
IgG F (ab’) 2 fragments immobilized in a line on the assay test strip. The 
complex bound to the immobilized F (ab’) 2 fragments and a reddish 
colored line appears. The appearance of the control line is evidence that 
the test functioned properly and the sample contained human IgG. A 
reddish purple control line will appear in the control Zone during the 
performance of all valid tests, whether or not the sample is reactive or 
negative for antibodies to HIV 1/ 2. The specimen continues to migrate 
past the control Zone into the final absorbent pad, which helps draw the 
specimen / conjugate mixture through the strip and clear any background 
color. The Test results are interpreted after 20 minutes but not more than 
45 minutes after introduction of the assay strip to the diluted specimen. 
Procedure: Specimen collection (Fig 4-7): 
Oral fluid sample collection swab is removed from the foil. Moderate 
pressure is applied while gently swabbing the upper gingiva back and 
forth with the cloth end of the swab. Beginning at one end of the mouth, 
swabbing is done gently and slowly until reaching the other corner of the 
mouth, covering the buccal mucosa. The other end of the swab is turned 
and is used for swabbing the lower gingiva. Immediately the swab is 
placed in the tube containing the sample buffer. The swab handle is 
grasped firmly and plunged up and down 6-8 times in the sample buffer 
rubbing both sides of the swab against the sides of the tube (Fig 8). The 
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swab is carefully removed and discarded in a biomedical waste container. 
Now the foil pouch is opened and the assay test strip is placed in the tube 
containing diluted specimen (fig 9) with arrow in the assay strip pointing 
downwards. Timer is set. The results are read after 20 minutes. The 
results are not read after 45 minutes. 
 Interpretation of Results (Fig 10) 
The Results are interpreted as follows by appreciating the test line and 
control line in the test strip. 
Reactive: The test is read as positive or reactive if Two lines appear in 
the assay strip (i.e.) in the test zone and control zone. 
Non-reactive: The test is read as Negative or non reactive if only one 
line appear in the assay strip (i.e.) in the control zone only. 
Invalid: The test is considered invalid if no control line is present. The 
invalid test should be repeated using a new test device and a second 
specimen.  
Precautions: 
Tests should be performed at ambient temperature 15-30 degrees. 
Universal precautions have to be taken care of when handling body fluids 
and assay strips. Patient asked not to drink, eat or smoke before the tests. 
Biomedical waste disposal system should be maintained to dispose the 
test specimens. 
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  Profoma 
 
Qualitative Immunoassay for HIV 1/2 Antibodies in Oral Mucosal Transudate
       -A Diagnostic Study 
    Department of Oral Medicine and Radiology 
Tamilnadu Government Dental college and Hospital, Chennai- 600 003 
 
 
Case no:     O.P. No:     Date: 
 
 
1. Name:  
 
2. Age:        3.Sex: 
 
4. Address: 
 
5. Occupation:      6.Income:  
 
 
7. Martial Status: 
 
 
8. Sample Category: 
 
Known positive:     Suspected case: 
 
 
 
9. Clinical Examinations 
 
1. Chief Complaint: 
 
 
 
2. History of presenting illness: 
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3. Past Medical history:  
  
 
S.no Complaints 
 
Yes/no Duration 
1 Weight loss 
 
  
2 Cough 
 
  
3 Fatigue 
 
  
4 Night sweats 
 
  
6 Fever 
 
  
7 Lymphadenopathy 
 
  
 
 
 
Specific Systems: 
 
S.no Systems Yes/No Symptoms Duration 
 
1 Respiratory system 
 
   
2 Gastro intestinal 
system 
 
   
3 Central nervous system
 
   
4 Cardio Vascular 
system 
 
   
5 Dermatological lesions 
 
   
6 
 
Psychological Status    
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4. General Examinations: 
 
i) Weight:        ii) Height: 
 
iii) Nutritional Status:  Good /   Moderate / Poor 
 
iv) Built:  Well built/ moderate/ Poor 
 
v) Vital Signs: 
 
 Blood pressure:      Respiratory rate: 
  
 Pulse Rate:      Temperature:  
 
 
vi) Constitutional signs:  
 
 Anemia:                                                                     Cyanosis: 
 
 Clubbing:                                                                     Jaundice: 
 
 
vii) Lymph node Examinations: 
 
 Group:        
 
Tenderness: 
 
 Number:     Size:   Consistency:  
 
4. HIV Positive cases: 
 
Contact history: 
a) Heterosexual 
b) Homosexual  
c) Vertical transmission 
d) Commercial Sex Worker 
e) Intravenous drug abuser 
f) Spouse 
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Local Examination: 
 Extra oral examination: 
 
 
 
 
 
Intra oral examination: 
 
Soft Tissue Examination: 
 
Upper Lip: 
 
  Lower Lip: 
 
  Commissures: 
 
 
Buccal Mucosa: 
 
   
  Tongue: 
 
 
Floor of mouth: 
 
   
Alveolar Mucosa: 
 
   
Gingiva: 
 
   
Hard palate: 
 
   
 
Soft palate: 
 
 
 43
 
 
 
Hard Soft tissue Examination: 
 
  No of teeth:     Decayed tooth: 
 
   
Attrition:     Abrasion: 
 
  Erosion:     Stains: 
 
 
 
Investigations: 
 
Routine Blood investigations: 
 
 TC:  DC:   ESR:   Hb%: 
 
 BT:     CT:   RBC count:   
   
 
Peripheral smear:  
 
 
 
Sputum for AFB: 
 
  
 
 
Chest x-ray:  
 
 
Other investigations: 
 
 
 
Treatment: 
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Oral Mucosal transudate test (OMT test) 
 
Region of interest: (Region where swab taken):   
    
Positive: 
 
 Negative:   
  
 
Known positive patients: 
  
 Duration of illness: 
 
 
 Type of test done: 
 
 
 ART (Anti retro viral therapy):  YES           / 
 NO 
 
  
 Duration of ART:   
 
 Suspected cases: 
 
 Type of test done:  
 
 Positive:  
 
 Negative: 
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PATIENT INFORMED CONSENT FORM 
 
Name:        Age:  
 
OP.No:        Sex: 
 
 
I    ……………………………  Aged   ……..   years is informed 
about the HIV diseases and about the study to test HIV infection 
in oral fluid. I hereby give my consent to be included as a 
participant in this diagnostic study. 
        
 Patients Signature:  
 
 
 
nehahËÆ‹ r«kj¥ got« 
 
 
…………………............................. v‹w eh‹, v¢.I.É g‰¿í«, 
thŒrij âut¤âš v¢.I.É. nehia f©Lão¡F« gÇnrhjid g‰¿í« ÉÇthf 
Tw¥g£l ã‹, ïªj gÇnrhjid¡F c£gl r«kâ¡»nw‹. 
 
nehahËÆ‹ ifbah¥g« 
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Results and Analysis 
      
      Tables and Charts 
 
 
 
Age: Table 1 
Group Statistics
25 36.40 11.113 2.223
25 37.24 10.910 2.182
GROUP
Known Positive
Suspected Cases
Age
N Mean Std. Deviation
Std. Error
Mean
 
 
 
Sex: Table 2 
Crosstab
18 17 35
72.0% 68.0% 70.0%
7 8 15
28.0% 32.0% 30.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Male
Female
Sex
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
Place:  Table 3 
 
 
Crosstab
19 22 41
76.0% 88.0% 82.0%
6 3 9
24.0% 12.0% 18.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Chennai
Out side chennai
Place
Total
Known
Positive
Suspected
Cases
GROUP
Total
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Contact history: (Known Positive) Table 4 
Crosstab
16 16
64.0% 64.0%
5 5
20.0% 20.0%
3 3
12.0% 12.0%
1 1
4.0% 4.0%
25 25
100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Heterosexual
Vertical transmission
Spouse
Intravenous drug User
Contact
History
Total
Known
Positive
GROUP
Total
 
 
 
Under ART: (Known Positive) Table 5 
 
Crosstab
11 0 11
44.0% .0% 22.0%
14 25 39
56.0% 100.0% 78.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Under ART/
Not
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
Chronic Cough: Table 6 
Crosstab
4 8 12
16.0% 32.0% 24.0%
21 17 38
84.0% 68.0% 76.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Chronic
cough
Total
Known
Positive
Suspected
Cases
GROUP
Total
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Recurrent Fever: Table 7 
Crosstab
2 6 8
8.0% 24.0% 16.0%
23 19 42
92.0% 76.0% 84.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Recurrent
Fever
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
 
Weight Loss: Table 8 
 
Crosstab
6 14 20
24.0% 56.0% 40.0%
19 11 30
76.0% 44.0% 60.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Weight
Loss
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
Fatigue/Tiredness: Table 9 
 
Crosstab
3 8 11
12.0% 32.0% 22.0%
22 17 39
88.0% 68.0% 78.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
fatigue/tiredness
Total
Known
Positive
Suspected
Cases
GROUP
Total
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H/O TB: Table 10 
 
Crosstab
2 2 4
8.0% 8.0% 8.0%
23 23 46
92.0% 92.0% 92.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
H/o
TB
Total
Known
Positive
Suspected
Cases
GROUP
Total
  
 
 
Others: Table 11 
 
Crosstab
1 7 8
4.0% 28.0% 16.0%
24 18 42
96.0% 72.0% 84.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Others
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
Oral Manifestations: 
 
Pseudomemebranous GROUP: Table 12 
 
Crosstab
2 4 6
8.0% 16.0% 12.0%
23 21 44
92.0% 84.0% 88.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Pseudomemebranous
Total
Known
Positive
Suspected
Cases
GROUP
Total
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Erythematous GROUP: Table 13 
 
Crosstab
5 10 15
20.0% 40.0% 30.0%
20 15 35
80.0% 60.0% 70.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Erythematous
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
 
Angular chelitis GROUP: Table 14 
 
Crosstab
2 5 7
8.0% 20.0% 14.0%
23 20 43
92.0% 80.0% 86.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Angular
chelitis
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
 
 
 
Non healing Ulcers: Table 15 
Crosstab
3 3 6
12.0% 12.0% 12.0%
22 22 44
88.0% 88.0% 88.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Non healing
Ulcers
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 51
 
 
Recurrent Apthous Ulcers: Table 16 
 
Crosstab
1 2 3
4.0% 8.0% 6.0%
24 23 47
96.0% 92.0% 94.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Recurrent Apthous
Ulcers
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
 
Malignancies GROUP: Table 17 
 
Crosstab
2 1 3
8.0% 4.0% 6.0%
23 24 47
92.0% 96.0% 94.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Malignancies
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
 
Salivary gland enlargements: Table 18 
Crosstab
25 25
100.0% 100.0%
25 25
100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
NoSalivary gland
enlargements
Total
Known
Positive
GROUP
Total
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Xerostomia: Table 19 
 
Crosstab
2 2
8.0% 8.0%
23 23
92.0% 92.0%
25 25
100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Xerostomia
Total
Known
Positive
GROUP
Total
 
 
 
 
Periodontitis: Table 20 
 
Crosstab
9 11 20
36.0% 44.0% 40.0%
16 14 30
64.0% 56.0% 60.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Periodontitis
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
 
Pigmentations: Table 21 
 
Crosstab
5 5
20.0% 20.0%
20 20
80.0% 80.0%
25 25
100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Pigmentations
Total
Known
Positive
GROUP
Total
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Others: Table 22 
Crosstab
2 10 12
8.0% 40.0% 24.0%
23 15 38
92.0% 60.0% 76.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Yes
No
Others
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
 
OMT GROUP: Table 23 
 
Crosstab
23 8 31
92.0% 32.0% 62.0%
2 17 19
8.0% 68.0% 38.0%
25 25 50
100.0% 100.0% 100.0%
Count
% within GROUP
Count
% within GROUP
Count
% within GROUP
Positive
Negative
OMT
Total
Known
Positive
Suspected
Cases
GROUP
Total
 
 
 
Chronic cough * Under ART/ Not: Table 24 
 
 
Crosstab
2 2 4
8.0% 8.0% 16.0%
9 12 21
36.0% 48.0% 84.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Chronic
cough
Total
Yes No
Under ART/ Not
Total
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Recurrent Fever * Under ART/ Not: Table 25 
 
Crosstab
2 0 2
8.0% .0% 8.0%
9 14 23
36.0% 56.0% 92.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Recurrent
Fever
Total
Yes No
Under ART/ Not
Total
 
 
 
 
 
Weight Loss * Under ART/ Not: Table 26 
 
Crosstab
2 4 6
8.0% 16.0% 24.0%
9 10 19
36.0% 40.0% 76.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Weight
Loss
Total
Yes No
Under ART/ Not
Total
 
 
 
 
Fatigue/tiredness * Under ART/ Not: Table 27  
 
Crosstab
2 1 3
8.0% 4.0% 12.0%
9 13 22
36.0% 52.0% 88.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
fatigue/tiredness
Total
Yes No
Under ART/ Not
Total
 
 
 
 55
 
 
H/o TB * Under ART/ Not: Table 28 
 
Crosstab
1 1 2
4.0% 4.0% 8.0%
10 13 23
40.0% 52.0% 92.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
H/o
TB
Total
Yes No
Under ART/ Not
Total
 
 
Others * Under ART/ Not: Table 29 
 
Crosstab
0 1 1
.0% 4.0% 4.0%
11 13 24
44.0% 52.0% 96.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Others
Total
Yes No
Under ART/ Not
Total
 
 
 
 
Pseudomemebranous * Under ART/ Not: Table 30 
 
Crosstab
0 2 2
.0% 8.0% 8.0%
11 12 23
44.0% 48.0% 92.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Pseudomemebranous
Total
Yes No
Under ART/ Not
Total
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Erythematous * Under ART/ Not: Table 31 
 
Crosstab
1 4 5
4.0% 16.0% 20.0%
10 10 20
40.0% 40.0% 80.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Erythematous
Total
Yes No
Under ART/ Not
Total
 
 
 
Angular chelitis * Under ART/ Not: Table 32 
 
Crosstab
0 2 2
.0% 8.0% 8.0%
11 12 23
44.0% 48.0% 92.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Angular
chelitis
Total
Yes No
Under ART/ Not
Total
 
 
Non healing Ulcers * Under ART/ Not: Table 33 
 
Crosstab
1 2 3
4.0% 8.0% 12.0%
10 12 22
40.0% 48.0% 88.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Non healing
Ulcers
Total
Yes No
Under ART/ Not
Total
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Recurrent Apthous Ulcers * Under ART/ Not: Table 34 
 
Crosstab
0 1 1
.0% 4.0% 4.0%
11 13 24
44.0% 52.0% 96.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Recurrent Apthous
Ulcers
Total
Yes No
Under ART/ Not
Total
 
 
 
 
Malignancies * Under ART/ Not: Table 35 
 
Crosstab
1 1 2
4.0% 4.0% 8.0%
10 13 23
40.0% 52.0% 92.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Malignancies
Total
Yes No
Under ART/ Not
Total
 
 
 
Salivary gland enlargements * Under ART/ Not: Table 36   
 
Crosstab
11 14 25
44.0% 56.0% 100.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
NoSalivary gland
enlargements
Total
Yes No
Under ART/ Not
Total
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Xerostomia * Under ART/ Not: Table 37 
 
Crosstab
1 1 2
4.0% 4.0% 8.0%
10 13 23
40.0% 52.0% 92.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Xerostomia
Total
Yes No
Under ART/ Not
Total
 
 
Periodontitis * Under ART/ Not: Table 38 
 
Crosstab
4 5 9
16.0% 20.0% 36.0%
7 9 16
28.0% 36.0% 64.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Periodontitis
Total
Yes No
Under ART/ Not
Total
 
Pigmentations * Under ART/ Not: Table 39 
 
Crosstab
2 3 5
8.0% 12.0% 20.0%
9 11 20
36.0% 44.0% 80.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Pigmentations
Total
Yes No
Under ART/ Not
Total
 
Others * Under ART/ Not: Table 40 
 
Crosstab
0 2 2
.0% 8.0% 8.0%
11 12 23
44.0% 48.0% 92.0%
11 14 25
44.0% 56.0% 100.0%
Count
% of Total
Count
% of Total
Count
% of Total
Yes
No
Others
Total
Yes No
Under ART/ Not
Total
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Sensitivity and Specificity: 
 
Table: 41 
OMT * Serum assay Crosstabulation
31 0 31
93.9% .0% 62.0%
2 17 19
6.1% 100.0% 38.0%
33 17 50
100.0% 100.0% 100.0%
Count
% within Serum assay
Count
% within Serum assay
Count
% within Serum assay
Positive
Negative
OMT
Total
Positive Negative
Serum assay
Total
 
 
 
 
 
Sensitivity of OMT Test: (31/33) × 100 = 93.93 %  
 The percentage of the results that will be positive when HIV is present.     
 
 
Specificity of OMT Test: 100%.  
The Percentage of the results that will be negative when HIV is not 
present  
 
 
Positive Predictive Value:   100% 
 
 
Negative Predictive Value:  89.4% 
 
 
 
 
 
 
 
 
 60
ROC Curve: (Receiver Operative Characteristics Curve) 
Graph1 
 
Case Processing Summary
17
33
Serum assay
Positivea
Negative
Valid N
(listwise)
Larger values of the test result variable(s) indicate
stronger evidence for a positive actual state.
The positive actual state is Negative.a. 
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Results and analysis 
This study is evaluated to test the sensitivity, specificity, positive 
predictive value and negative predictive value of Calypte’s AWARETM 
Oral mucosal transudate rapid test for detecting antibodies to HIV 1/ 2 in 
oral fluid and is compared with standard serum rapid test approved by 
National AIDS control Organization. Sample sizes of 50 patients were 
selected and grouped in two groups namely Known Sero-positive 
(Group1) and suspected cases of HIV (Group 2). Group 1 includes 25 
cases (50%) of HIV Known Sero-positive HIV infected individuals who 
came to the dept of Oral Medicine and Radiology for various dental 
treatments. Group 2 includes 25 cases (50%) of clinically suspected cases 
of HIV infection. All patients were under age group 20- 60yrs. Out of 50 
patients the mean age group of Group 1 were 36 and Group 2 was 
37(Table 1). Out of which 35 were males 15 were females (Table 2), 41 
belonging to Chennai and 9 were outsiders (Table 3). With their informed 
consent and Pre counseling Oral Mucosal transudate test were carried out 
and the results were analyzed using SPSS  software. Of Known HIV 
Sero-positive individuals the contact history revealed 64% acquired 
infection through heterosexual route, 20% through vertical transmission, 
12% through spouse, and 4% through intravenous drug usage with 22% 
under ART (Table 4). 
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On examining, general manifestations of the individuals of both groups, 
24% were with chronic cough(Table 6), 16% with recurrent fever(Table 
7), 40% with weight loss(Table 8), 22 % with fatigue and tiredness(Table 
9), 8% with previous / present attack of tuberculosis(Table  10) and 16% 
with other general manifestations(Table 11). Analyzing the presence of 
oral manifestations in the samples selected, 12% were affected with 
pseudo membranous candidiasis (Table 12), 15% with erythematous 
candidiasis (Table 13), 14% with angular chelitis (Table 14), 12% with 
non healing ulcers (Table 15), 6% with recurrent apthous ulcers (Table 
16), 20% with periodontal related lesions (gingivitis, periodontitis, 
necrotizing gingivitis and periodontitis) (Table 20) and 12% with other 
oral manifestations (Table 22).  In Known positive group 8% were 
affected with xerostomia (Table 19) and 20% were having mucosal 
pigmentations (Table 21). Known Positive group (group1) were divided 
into two groups namely the persons who were taking ART and persons 
who were not under ART treatment. Out of 25 cases of Group 1 11(44%) 
patients were under ART   and 14 (56%) were not under ART. Analyzing 
the samples under ART of Known positive patients with Non ART group, 
8% were affected with cough (Table 24) in both ART group and non-
ART group, 2patients( 8%) with recurrent fever in ART group whereas 
none was affected in not under ART group (Table 25), 8% with weight 
loss in ART group whereas 16% were affected in not under  ART group 
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(Table 26), 8% with fatigue and tiredness in ART group whereas only 4% 
in not under ART group (Table 27), and 4 % with history of attack of 
tuberculosis in both ART and not  under ART group (Table 28) which 
was significantly lower than patients under non ART group. Comparing 
the oral manifestations of patients with ART and patients not under ART 
of known positive patients, people with pseudo membranous candidiasis 
under ART group was 0% whereas patients with not under ART group 
was 8%(Table 30). Patients suffering from Erythematous candidiasis in 
ART group were 4% and in not under ART group was 16 % (Table 31). 
Angular chelitis was 0% in ART group and 8% in patients not under ART 
group (Table 32), non healing ulcers was 4% in ART group and 8% in 
patients not under ART group (Table 33), Recurrent Apthous ulcers were 
0% in ART group and 4% in patients not under ART group (Table 34), 
salivary enlargements were 44% in ART group (Table 35) and 56% in 
patients not under ART group , periodontitis were 16 in ART group and 
20% in patients not under ART group(Table 38), pigmentations were 8% 
in ART group  and 12% in patients not under ART group(Table 39). The 
data clearly shows that there is a decrease in both general and oral 
manifestations in patients under ART group. Analyzing the results of oral 
mucosal transudate test, Out of 25 patients of Known Seropositive group 
23 showed positive results in OMT test; where as 2 patients were 
negative to OMT test. In Group 2 of Suspected cases of HIV individuals 
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8 patients (32%) were positive to OMT test and 17 patients (68%) were 
negative to OMT test (Table 41). Group 2 patients either positive or 
negative to OMT test were subjected to Standard Rapid Serum assays to 
test HIV infection and the results were compared with OMT test results. 
17 patients who were negative to OMT test were also negative to Rapid 
serum assay and 8 patients who were positive to OMT test were also 
positive to Rapid serum assay (Table 41). From the statistical analysis the 
sensitivity of the OMT rapid screening assay was 93.93% and specificity 
was 100%. The positive predictive value was computed to be 100% with 
a negative predictive value of 87.4%. Receptor Operator characteristic 
curve (Graph 1) which is plotted against sensitivity and specificity of 
OMT Test clearly shows the area under the curve is 0.970 indicating that 
OMT test is better useful as a screening test. 
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      Discussion 
 The main aim of this study is to evaluate the efficacy of Oral Fluid 
in diagnosing and screening individuals with HIV infection and to 
compare the Sensitivity and Specificity of Oral Mucosal transudate test 
with standard serum screening test. Epidemiological studies need easier 
tools to evaluate HIV prevalence particularly in high risk groups under 
difficult field conditions. Testing Saliva/ Oral mucosal antibody with 
accurate immunoassay could serve as an alternative to serum assays. 
Salivary assays could be efficient and non invasive epidemiological tool 
for HIV testing. 
 Whole saliva is a mixture of oral fluids and includes secretions 
from both minor and major salivary glands , in addition to several 
constituents of non-salivary origin such as gingival crevicular fluid 
(GCF), expectorated bronchial and nasal secretions , serum and blood 
derivatives from oral wounds, bacteria and bacterial products, viruses and 
fungi, desquamated epithelial cells, other cellular components and food 
debris. There are several ways by which the serum constituents that are 
not part of normal salivary constituents can reach saliva. A serum 
molecule reaching saliva by diffusion must cross five barriers; the 
capillary wall, interstitial space , basal cell membrane of the acinus 
cell/duct cell, cytoplasm of the duct cell, luminal cell membrane. Serum 
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constitituents are also found in whole saliva as a result of GCF outflow 
(Eliaz Kaufman, Ira B. Lamster 2002)10. Depending on the degree of 
inflammation in gingival, GCF is a serum transudate or an inflammatory 
exudate that contains serum constituents. This Study aims at detection of 
IgG anti HIV antibody in oral fluid and hence called as Oral Mucosal 
Transudate test. The antigens to HIV-1(gp 41) and HIV-2 (gp 36) were 
impregnated in the assay strip to test the presence of HIV antibody to 
either HIV type 1 virus or Type 2 virus. So this test qualitatively analyses 
the presence of antibodies to HIV infection of both type 1 and type 2. In 
this study sample size of 50 cases were selected and divided in two 
groups namely Known Sero-Positive patients and Suspected cases of HIV 
infection. Oral examination is an important part of any physical 
examination and nowhere is this more important than in the case of 
suspected HIV infection (Greenspan.D 1993)76. As by saying “Mouth is 
a mirror of systemic diseases” oral manifestations of HIV affected 
individuals are typical and in most cases be an indicator of poor 
immunosuppression and HIV infection. Suspected cases were selected 
accordingly by the presence of any one or more of the following 
conditions namely 
 High Risk group individual 
  Homosexuals 
  Extramarital Sex 
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  Intravenous drug users 
  Sex Workers 
  Children of HIV infected individuals 
  Occupationally Risk groups 
  
General manifestations: 
  Chronic Cough for more than 6 months 
  Recurrent Fever for more than 6 months 
  Sudden Weight loss of about 10kgs 
  Fatigue/ Tiredness 
  H/O tuberculosis 
  Others 
   Severe Dermatological Lesions 
   Malignancies 
   Respiratory and others serious infections 
  
Oral manifestations:  
  Oral candidiasis 
   Psedomembranous 
   Atrophic/ erythemaotus 
   Angular Chelitis 
  Non Healing Ulcers 
  Recurrent Apthous Ulcers. 
  Severe Periodontits/ Gingivitis with necrosis. 
  Others 
   Malignancies 
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According to this study patients under ART group showed few 
general and oral manifestations of the HIV infection comparing with 
Patients under Non ART group. Also HIV positive patients tested under 
suspected cases of HIV infection were presented with increased severity 
of oral manifestations than Known Seropositive HIV individuals. From 
these results it is evident that oral manifestations of HIV infections are 
more common in untreated, unknown cases of HIV individuals than with 
patients under HAART treatment and regular follow up of HIV infection. 
Oral Manifestations and other systemic manifestations subsequently 
reduced after starting treatment with antiretroviral drugs. However side 
effects of HAART including xerostomia, mucosal pigmentations and 
salivary gland enlargements increase in frequency of patients under ART. 
According to this study the sensitivity of Oral Mucosal Transudate test is 
93.93 %, specificity is 100%, the positive predictive value is 100% and 
negative predictive value is 89.4%. Receptor Operator characteristic 
curve of this study plotted against the sensitivity and specificity showed 
and area of 0.90 under the curve which clearly indicated that this test can 
be used as a Screening test to diagnose HIV infection. The Dental 
clinicians are more prone to HIV cross infections and it is necessary for 
the dental clinicians to cross check individuals affected with HIV 
infection to prevent HIV cross infection. All staffs, working personnel, 
dental surgeons and patients have to be protected against cross infections 
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of HIV. Oral Mucosal transudate test , an easy, simple , non invasive 
method for screening HIV infection would be a valuable tool and a chair 
side diagnostic aid for Oral medicine Specialist to screen patients 
undergoing dental treatment and for those clinically suspected cases of 
HIV infection. Application of Oral Fluid as a diagnostic aid for HIV 
infection would bring a remarkable change in dentistry35 and also it 
would be a better screening tool for epidemiological studies and 
screening for HIV infection in high risk group individuals35. In this study 
the specificity of HIV infection is 100% indicating that this test is a valid 
screening test. However large sample size and further longitudinal studies 
is necessary to use this test as a screening test and validating this test as 
standard test for HIV infection.  
 
 Dental Considerations in HIV patients 
Oral health considerations for persons infected with HIV focus on 
provision of dental care and oral conditions associated with their 
underlying disease. An appropriate work-up for an HIV infected patient 
needs to ascertain a patient overall health immune status , prognosis , 
presence and history of opportunistic infections, risk for developing more 
severe opportunistic infections and oral lesions, current medications and 
chance for long term survival. As a general rule, no dental modifications 
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are required for patient based on their HIV status4,70. Most individuals 
presenting to Out-patient dental care are sufficiently healthy to tolerate all 
types of dental procedures, ranging from scaling to implants.   The major 
concerns are impaired homeostasis, susceptibility to dentally induced 
infections, drug interactions and the patient ability to withstand stress and 
trauma of dental procedures. Even when patients CD4 count are very low 
they are not more susceptible to dentally induced bacteraemia. There are 
no indications for routine use of antibiotic prophylaxis based on patients 
HIV status. However patients with neutrophil count below 500-700 cells 
/mm3 require antibiotic1. Furthermore some patients maybe at a risk for 
developing sub acute bacterial endocardititis if they are former 
intravenous drug user. Most side effects from medications used to treat 
HIV disease are associated with Xerostomia. Drug interactions with 
medications commonly used in a dental setting also exist. Treatment 
planning for HIV positive patients needs to address numerous 
considerations. The vast majority of patients have some degree of 
Xerostomia ranging from mild to severe. Thus when performing simple 
restorative procedures or fabricating fixed / removable prosthodontics, 
the type of restorative material, long term use and maintenance of a 
restoration need to be taken into considerations70  
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Summary and Conclusion 
HIV rapid testing devices are easy to use, do not require 
refrigeration and are less expensive to run, portable with a longer shelf 
life. They are more adaptable for field use and screening of high risk and 
far to reach populations mostly located in resource poor settings14,35,37. 
Infact, they have reduced the time between testing and release of results 
to minutes from days or weeks when compared with other assays. The 
need for regularly updating diagnostic principles and methods & 
continuous evaluation of test kits to make sure that they can detect the 
newly emerging viral strains is important.  HIV 1/ 2 OMT evaluation 
result falls within the WHO recommended range of tests to be used for 
HIV diagnosis. 
In this Study sensitivity and specificity of   HIV 1/ 2 OMT test is 
evaluated in a sample size of 50 patients divided in two groups namely, 
known Sero-positive and suspected cases of HIV infection. The 
Sensitivity of the test is 93.93%, specificity is 100% with positive 
predictive value corresponds to 100% and negative predictive value 
corresponds to 89.4%. From the results it’s very clear that Oral mucosal 
transudate test can be used as a screening test for large scale high risk 
group individuals in a community, suspected patients in dental health care 
settings. Though a confirmatory testing is required using a standard 
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serum test before disclosing positive result to a patient. Cross infections 
in a dental community or health care workers can be readily minimized 
when Oral mucosal transudate test is used in dental care patients. CDC 
continues to encourage the use of rapid HIV tests20-22,35 because they 
increase the number of persons who are tested and who receive their tests 
results. Regardless confirmatory testing is required to confirm, all 
patients should be informed that reactive rapid oral fluid tests are 
preliminary and require confirmation35. Overall, Oral fluid rapid tests 
have performed well and make HIV testing possible in many venues 
where performing serum tests are impractical for screening. The main 
advantage of rapid HIV oral fluid tests includes increased availability and 
acceptability of testing among populations at high risk for HIV infection 
and is simple, easy, non-invasive, user friendly52 and prevents cross 
infection to health care workers. From this study we conclude that Oral 
fluid can be used as an efficient Screening tool for diagnosis of HIV 
infection35. Further longitudinal studies, increased sample size is required 
to test the efficacy of Oral Fluid / Saliva in diagnosing HIV infection and 
using OMT test as a screening test in practice.   
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